105
document
Switching patients with asthma from chlorofluorocarbon ( CFC ) albuterol to hydrofluoroalkane-134a ( HFA ) albuterol . Chlorofluorocarbon ( CFC ) propellants deplete stratospheric ozone . Production and use of CFCs , except for certain critical exemptions , has been prohibited by the Montreal Protocol . Use of CFCs as propellants in metered-dose inhalers ( MDIs ) is still allowed , but the U.S. Food and Drug Administration is planning the transition to alternative propellants for use in MDIs . Hydrofluoroalkane-134a ( HFA ) , a non-ozone-depleting propellant , has been used to reformulate albuterol ( HFA albuterol ) . This study evaluates whether comparable safety and efficacy continues for 12 weeks after patients with asthma are switched from CFC albuterol to HFA albuterol . Patients with asthma stabilized on CFC albuterol during a 12-week safety and efficacy trial were randomized to either continue receiving CFC albuterol or to be switched to receive HFA albuterol in a yearlong safety and efficacy trial . Safety and efficacy were compared over the first 12 weeks of the yearlong trial between patients who had remained on CFC albuterol and those who had been switched to HFA albuterol . Bronchodilator efficacy was evaluated by serial spirometry for 6 hr after the patients self-administered the study drug in the clinic . Safety was assessed by measuring changes in pulse rate , blood pressure , and electrocardiogram ( ECG ) intervals after dosing with study drug , monitoring adverse events , and performing prestudy and poststudy laboratory testing and physical examinations . No significant differences in bronchodilator efficacy between the patients continuing to receive CFC albuterol and those switched to HFA albuterol were found in the 12 weeks after the switch . No differences between the two products were found for changes in pulse rate , blood pressure , and ECG intervals . Adverse event profiles were similar for the two products , except the patients remaining on CFC albuterol reported increased asthma symptoms and rhinitis significantly more often than the patients switched to HFA albuterol . No clinically meaningful changes in laboratory tests or physical examinations were found in either treatment group . Patients with asthma switched from CFC albuterol to HFA albuterol receive comparable bronchodilation with a similar safety profile as those continuing to receive CFC albuterol .
106
Intervention_Pharmacological
hydrofluoroalkane-134a ( HFA ) albuterol .
107
Intervention_Pharmacological
Hydrofluoroalkane-134a ( HFA )
108
Intervention_Pharmacological
switched from CFC albuterol to HFA albuterol
109
Intervention_Physical
either continue receiving
110
Intervention_Pharmacological
CFC albuterol
111
Intervention_Physical
to be switched to receive
112
Intervention_Pharmacological
HFA albuterol
113
Intervention_Physical
in a yearlong safety and efficacy trial
114
Intervention_Physical
HFA albuterol
115
Intervention_Physical
HFA albuterol
116
Outcome_Other
Safety and efficacy
117
Outcome_Other
Bronchodilator efficacy
118
Outcome_Other
serial spirometry
119
Outcome_Other
Safety
120
Outcome_Adverse-effects
changes in
121
Outcome_Physical
pulse rate
122
Outcome_Adverse-effects
,
123
Outcome_Physical
blood pressure
124
Outcome_Adverse-effects
, and
125
Outcome_Physical
electrocardiogram ( ECG )
126
Outcome_Adverse-effects
intervals
127
Outcome_Adverse-effects
monitoring adverse events
128
Outcome_Physical
laboratory testing and physical examinations
129
Outcome_Adverse-effects
.
130
Outcome_Other
bronchodilator efficacy
131
Outcome_Physical
pulse rate
132
Outcome_Adverse-effects
,
133
Outcome_Physical
blood pressure
134
Outcome_Adverse-effects
, and
135
Outcome_Physical
ECG intervals
136
Outcome_Adverse-effects
. Adverse event profiles
137
Outcome_Adverse-effects
changes